Identification and quantification of the basal and inducible Nrf2-dependent proteomes in mouse liver: Biochemical, pharmacological and toxicological implications  by Walsh, Joanne et al.
J O U R N A L O F P R O T E O M I C S 1 0 8 ( 2 0 1 4 ) 1 7 1 – 1 8 7
Ava i l ab l e on l i ne a t www.sc i enced i r ec t . com
ScienceDirect
www.e l sev i e r . com/ loca te / j p ro tIdentification and quantification of the basal and
inducible Nrf2-dependent proteomes in mouse
liver: Biochemical, pharmacological and
toxicological implicationsJoanne Walsha, Rosalind E. Jenkinsa, Michael Wonga, Adedamola Olayanjua,
Helen Powellb, Ian Copplea, Paul M. O’Neilla, Christopher E.P. Goldringa,
Neil R. Kitteringhama,⁎, B. Kevin Parka
aMRC Centre for Drug Safety Science, School of Biomedical Sciences, University of Liverpool, Sherrington Buildings, Liverpool, Merseyside L69 3GE,
United Kingdom
bAstraZeneca R&D Alderley Park, Safety Assessment UK, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, United KingdomA R T I C L E I N F O⁎ Corresponding author. Tel.:+44 151 794 5548
E-mail addresses: joanne.henry@liv.ac.uk
a.olayanju@liv.ac.uk (A. Olayanju), Helen.pow
(P.M. O’Neill), chrissy@liv.ac.uk (C.E.P. Goldri
http://dx.doi.org/10.1016/j.jprot.2014.05.007
1874-3919/© 2014 The Authors. Publish
(http://creativecommons.org/licenses/by/3.0/A B S T R A C TArticle history:
Received 19 August 2013
Accepted 13 May 2014
Available online 21 May 2014The transcription factor Nrf2 is a master regulator of cellular defence: Nrf2 null mice (Nrf2(−/−))
are highly susceptible to chemically induced toxicities. We report a comparative iTRAQ-based
study in Nrf2(−/−) mice treated with a potent inducer, methyl-2-cyano-3,12-dioxooleana-1,9(11)
dien-28-oate (CDDO-me; bardoxolone -methyl), to define both the Nrf2-dependent basal
and inducible hepatoproteomes. One thousand five hundred twenty-one proteins were fully
quantified (FDR <1%). One hundred sixty-onewere significantly different (P < 0.05) betweenWT
and Nrf2(−/−) mice, confirming extensive constitutive regulation by Nrf2. Treatment with
CDDO-me (3 mg/kg; i.p.) resulted in significantly altered expression of 43 proteins at 24 h
in WT animals. Six proteins were regulated at both basal and inducible levels exhibiting the
largest dynamic range of Nrf2 regulation: cytochrome P4502A5 (CYP2A5; 17.2-fold), glutathione-
S-transferase-Mu 3 (GSTM3; 6.4-fold), glutathione-S-transferase Mu 1 (GSTM1; 5.9-fold),
ectonucleoside-triphosphate diphosphohydrolase (ENTPD5; 4.6-fold), UDP-glucose-6-
dehydrogenase (UDPGDH; 4.1-fold) and epoxide hydrolase (EPHX1; 3.0-fold). These proteins,
or their products, thus provide a potential source of biomarkers for Nrf2 activity. ENTPD5 is of
interest due to its emerging role in AKT signalling and, to our knowledge, this protein has not
been previously shown to be Nrf2-dependent. Only two proteins altered by CDDO-me in WT
animals were similarly affected in Nrf2(−/−) mice, demonstrating the high degree of selectivity
of CDDO-me for the Nrf2:Keap1 signalling pathway.
Biological significance
The Nrf2:Keap1 signalling pathway is attracting considerable interest as a therapeutic target for
different disease conditions. For example, CDDO-me (bardoxolone methyl) was investigated inKeywords:
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172 J O U R N A L O F P R O T E O M I C S 1 0 8 ( 2 0 1 4 ) 1 7 1 – 1 8 7clinical trials for the treatment of acute kidney disease, and dimethyl fumarate, recently
approved for reducing relapse rate in multiple sclerosis, is a potent Nrf2 inducer. Such
compounds have been suggested to act throughmultiplemechanisms; therefore, it is important
to define the selectivity ofNrf2 inducers to assess thepotential for off-target effects thatmay lead
to adverse drug reactions, and to provide biomarkers with which to assess therapeutic efficacy.
Whilst there is considerable information on the global action of such inducers at themRNA level,
this is the first study to catalogue the hepatic protein expression profile following acute exposure
to CDDO-me in mice. At a dose shown to evoke maximal Nrf2 induction in the liver, CDDO-me
appeared highly selective for known Nrf2-regulated proteins. Using the transgenic Nrf2(−/−)
mousemodel, it could be shown that 97% of proteins induced in wild typemice were associated
with a functioning Nrf2 signalling pathway. This analysis allowed us to identify a panel of
proteins that were regulated both basally and following Nrf2 induction. Identification of these
proteins, which display a largemagnitude of variation in their expression, provides a rich source
of potential biomarkers for Nrf2 activity for use in experimental animals, and which may be
translatable to man to define individual susceptibility to chemical stress, including that
associated with drugs, and also to monitor the pharmacological response to Nrf2 inducers.
© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the
CC BY license (http://creativecommons.org/licenses/by/3.0/).1. Introduction
Maintenance of a stable intracellular environment is a prerequi-
site for normal physiological function. In a manner, somewhat
analogous to the immune system,mammalian cells exhibit both
innate and adaptive properties that allow them towithstand and
respond to a variety of stress stimuli including environmental,
dietary and, more recently, pharmaceutical-induced stresses. At
the core of this cellular defence strategy is the Keap1:Nrf2
signalling pathway, which regulates expression of a battery of
antioxidant proteins and enzymes involved in a variety of
mechanisms that function to counter noxious stimuli. In the
absence of stress, the transcription factor Nrf2 is retained in the
cytoplasm through interaction with its inhibitor protein, Keap1,
which targets Nrf2 for ubiquitination and proteasomal degrada-
tion. Thus, Nrf2 is rapidly recycled with a half-life of approxi-
mately 20 min [1]. Upon exposure to stress stimuli, such as
reactive oxygen species and electrophiles, Nrf2 is stabilized and
able to translocate to the nucleus where it transactivates target
genes that possess an antioxidant responsive element (ARE) in
their promoter regions. The precise mechanism through which
the Keap1:Nrf2 interaction is disrupted is not fully understood,
but the widely accepted ‘hinge and latch’ model [2] envisages
that the function of the Keap1 dimer is disrupted by direct
modification of sensitive cysteine residues, preventing Nrf2
ubiquitination and blocking access to Keap1 binding sites for
newly synthesized Nrf2 molecules. Whilst Keap1-targeted
ubiquitination results in highly efficient degradation of Nrf2, it
is clear that low levels of Nrf2-mediated signalling do still occur
under basal conditions, as evidenced by studies onNrf2(−/−) mice.
Although mice deficient in Nrf2 appear phenotypically normal,
examination at the molecular level shows clear differences in
gene expression profiles, confirming a constitutive role for Nrf2
in the orchestration of cellular defence [3,4].
In the context of chemical stress, Nrf2(−/−) mice are more
vulnerable to the deleterious effects of chemicals toxic to the
liver, as well as to several other organs. The animals show
enhanced susceptibility to the hepatotoxicity associated with
paracetamol [5,6], carbon tetrachloride [7] and ethanol [8], as
well as drug-induced injury to the lungs [9,10] and colon [11].With respect to liver, basal differences between wild type
and Nrf2(−/−) mice have been shown both by gene micro-
array studies and by targeted protein analysis [4,12,13]. More
recently, we conducted a global protein expression analysis
using iTRAQ-based proteomics and identified two discrete
pools of hepatic proteins which display differential expression
profiles in wild type and Nrf2(−/−) mice: cytoprotective proteins
and proteins involved in lipidmetabolism [3]. Pathway analysis
confirmed that the cytoprotective proteins found to be down-
regulated in Nrf2(−/−) mice were predominantly phase II drug
metabolizing enzymes or those involved in the glutathione
system. In contrast, proteins involved in lipid metabolismwere
primarily over-expressed in Nrf2(−/−) mice, indicating an unex-
pected negative regulation of the fatty acid synthetic pathway.
2-Cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid (CDDO)
was synthesised for its anti-inflammatory properties via the
modificationof theAandC rings of oleanolic acid [14]. CDDOwas
found to potently inhibit nitric oxide production, and analogues
including CDDO methyl ester (CDDO-me) and the imidazole
derivative (CDDO-im) were subsequently synthesised with the
aim of optimising potency and bioavailability [15,16]. A link
betweenNrf2 induction and CDDO treatmentwas first identified
in a study in which the synthetic triterpenoid was shown to
potently induce the phase II response in mouse embryonic
fibroblasts [17], a response that was abolished in Nrf2-deficient
cells. In a later study, CDDO and its derivatives were shown to
induce Nrf2 protein levels in vitro along withmRNA levels of the
Nrf2 target gene haem oxygenase 1 (Ho-1) [18]. Furthermore, the
Nrf2 target NAD(P)H dehydrogenase [quinone] 1 (Nqo1) was
subsequently found to be transcriptionally activated inCDDO-im
and CDDO-me treated mice, with induction seen in the liver,
lung and small intestine after a single dose [19].
Recently, CDDO-me (under the name bardoxolone methyl)
has undergone clinical evaluation for the treatment of chronic
kidney disease in diabetic patients [20]. Whilst the therapeutic
benefit was promising, the development was terminated in
phase III due to a high incidence of adverse reactions [21].
Nevertheless, there remains considerable interest in this class
of compounds, particularly in the field of cancer chemotherapy
[22]. The precisemechanism bywhich CDDO and its derivatives
173J O U R N A L O F P R O T E O M I C S 1 0 8 ( 2 0 1 4 ) 1 7 1 – 1 8 7mediate their therapeutic effects remains unclear. Preclinical
studies have shown that as well as activating the Nrf2 pathway,
the compounds also modulate signalling associated with the
PPAR-γ receptor [23] and JAK-STAT pathway [24,25] and inhibit
both the constitutive and inducible activation of NF-κB [26–28].
Given the side effects identified following repeat administration
of CDDO-me to some patients, it is becoming increasingly
important to define the effects of CDDO-me at the mRNA and
protein level and to ascribe these effects as Nrf2 dependent or
independent actions. Furthermore, in order to assess directly
the efficacy of CDDO-me and other Nrf2 inducers, biomarkers
that specifically reflect both constitutive and induced levels of
Nrf2 activity would be invaluable to define the level of human
Nrf2 variability and its activation in response to chronic drug
exposure. There is consequently a clear imperative to generate
a definitive list of Nrf2-regulated genes, since this may yield
proteins or protein products that are potential biomarkers for
such translational research.
Whilst a comprehensive comparative proteomic characteri-
sation of the liver tissue from Nrf2(−/−) and wild type mice has
been conducted at the constitutive level, to date no equivalent
analysis of the inducible protein profile has been carried out. For
that reason, this studywas designed to define the Nrf2-inducible
hepatic proteomeusing the potentNrf2 activator, CDDO-me. The
Nrf2(−/−) mouse provides a useful tool to define which of the
changes in protein expression following CDDO-me administra-
tion are Nrf2-dependent. When used alongside pharmacological
induction of Nrf2, the Nrf2(−/−) model allows the characterisation
of the dynamic range of Nrf2 expression and thus allows the
identification of candidate biomarkers that might be used to
monitor Nrf2 induction in both pre-clinical and translational
studies. Through the administration of CDDO-me to Nrf2(−/−) and
wild typemice, our aimwas to investigate the hepatic proteomic
profile of mice treated with CDDO-me and to characterise the
differences in protein expression in the absence of Nrf2.2. Materials and methods
2.1. Materials
Eight-plex isobaric tags for relative and absolute quantification
(iTRAQ) protein labelling kit/reagents were purchased from AB
Sciex (Framingham, MA). Sequencing grade trypsin and the
ImProm-II Reverse Transcription System were obtained from
Promega UK (Southampton, Hants, UK). The RNeasy Mini-kit
was purchased from Qiagen (Crawley, UK). The RNA 6000 Nano
Kit was from Agilent (Berkshire, UK). ATP citrate lyase (ACL),
NQO1 and actin antibodies were from Abcam (Cambridge, UK).
CDDO-me was synthesised by Michael Wong (Department
of Chemistry, University of Liverpool, UK). All other reagents
were of analytical grade and quality and purchased from Sigma
(Poole, Dorset, UK).
2.2. Animals
All experiments were undertaken in accordance with the
Animals (Scientific Procedures) Act 1986, and approved by the
University of Liverpool Animal Ethics Committee. Generation
of the Nrf2(−/−) mouse and genotyping of progeny have beendescribed elsewhere [29,30]. Non-fasted male littermate wild
type and Nrf2(−/−) mice (C57BL6J background) of 10–12 weeks of
age were used throughout the study. Mice were housed at 19–
23 °C under 12 h light/dark cycles and given free access to
food and water.
In order to determine the optimal dose of CDDO-me and a
time of induction that resulted in a strong downstream protein
response, both dose response and time-course preliminary
studies were conducted in wild type mice using NQO1 as a
prototypic target protein. For thedose optimisation experiment,
mice were administered a single i.p. dose of CDDO-me (0, 0.1,
0.3, 1, 3 or 10 mg/kg in 100 μL DMSO; n = 2) at 10 a.m. At 24 h
after dosing the animals were culled by exposure to a rising
concentration of CO2 followed by cardiac puncture. Livers were
removed immediately, snap-frozen in liquid N2 and stored at
−80 °C. For the time-course assessment,micewere killed at 2, 4,
6 or 24 h after CDDO-me (3 mg/kg; n = 4) and the identical
subsequent procedure was followed.
For the proteomic study, livers were harvested from wild
type and Nrf2(−/−) mice that had been dosed with 3 mg/kg
CDDO-me or DMSO vehicle control (n = 6), using the protocol
as described for the pilot study.
2.3. RNA isolation and quality determination
RNA isolation was performed using the RNeasy Mini-kit
according to themanufacturer’s instructions, and RNA concen-
tration was determined using a NanoDrop ND-1000 (Labtech,
East Sussex, UK). The quality of the RNA was determined using
the Agilent RNA 6000 Nano Kit according to themanufacturer’s
instructions, with samples analysed using the Agilent 2100
bioanalyzer (Agilent, Berkshire, UK).
2.4. cDNA synthesis
cDNA synthesis was carried out using the Promega ImProm-II
Reverse Transcription System according to the manufac-
turer’s instructions, with some minor modifications: 4 μL of
RNA at a concentration of 0.5 μg/μL was combinedwith 1 μL of
random primer solution, and nuclease-free dH2O was added
to give a final volume of 15 μL. The solution was incubated
(70 °C; 5 min) and then cooled on ice. A master-mix contain-
ing ImProm-II reaction buffer, 6 mM MgCl2, dNTP mix and
ImProm-II reverse transcriptase in a final volume of 20 μL was
added to the RNA solution. Strands were annealed (25 °C;
5 min) andextended (42 °C; 1 h) before the reverse transcriptase
was inactivated (70 °C; 15 min).Nuclease-free dH2O (160 μL)was
added to each tube and cDNA concentration was subsequently
determined using the NanoDrop.
2.5. Microfluidic cards
Microfluidic cards were designed based on the results of
previous proteomic analysis comparing the hepatic profile of
basal wild type and Nrf2(−/−) mice [3]. The cards included well
established Nrf2-regulated genes, genes encoding proteins
identified as Nrf2-regulated in iTRAQ analysis and genes
encoding proteins that were not identified by iTRAQ but were
associated with pathways identified by MetaCore analysis.
Cards were custommade by Applied Biosystems (Paisley, UK).
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were run ina randomisedorder, asdeterminedusing random.org
(http://www.random.org/), across 5 TaqMan array cards. A pool
of cDNA fromall sampleswas runoneachcard so that data could
be compared across plates.
cDNAwas diluted in nuclease-free dH2O to a concentration
of 2 ng/μL cDNA and analysed according the manufacturer’s
instructions using the 7900HT Fast Real-Time PCR System
(ABSciex).
2.6. Microfluidic data analysis
Data was analysed using the comparative CT method (ΔΔCT).
CT values were determined using the RQ manager 1.2
component of the 7900HT Fast System software. The thresh-
old was manually set to a value of 0.3 for all plates. Gene
expression was quantified relative to the sample pool run on
the same plate and normalised to 18S gene expression. Relative
expression of genes was compared in wild type vehicle treated
and CDDO-me treated mice, vehicle treated wild type and
Nrf2(−/−) mice andNrf2(−/−) vehicle treated and CDDO-me treated
mice by two way ANOVA with Tukey multiple comparison
testing. Statistical analysis was performed using StatsDirect
version 2.7.9 (StatsDirect Ltd, Altrincham, UK).
2.7. iTRAQ labelling and mass spectrometric analysis of liver
homogenates
Liver samples (~100 mgwet weight) were dounce homogenised
in 0.5 M triethylammonium bicarbonate/0.1% SDS and subject-
ed to a freeze–thaw cycle (−80 °C for 30 min), before sonication
(3 x 10 s at 5 μm amplitude) and centrifugation at 17,000g for
10 min at 4 °C. Aliquots of each sample (75 μg protein [31]) were
denatured and reduced and sulphydryl groups were capped
with MMTS according to the manufacturer’s 8-plex protocol
(Applied Biosystems, CA). The samples were digested with
trypsin overnight, labelled with iTRAQ isobaric tags (113–121)
and mixed in equal proportions. Unbound reagent and trypsin
were removed by cation exchange chromatography. Fractions
were desalted using a macroporous C18 column (Agilent, Santa
Clara, CA) on a Vision workstation and dried by centrifugation
under vacuum (SpeedVac, Eppendorf). Samples were analysed
on a Triple TOF 5600 mass spectrometer (AB Sciex) and were
delivered into the instrument by automated in-line liquid
chromatography Eksigent NanoUltra cHiPLC System mounted
with microfluidic trap and analytical column (15 cm × 75 μm)
packed with ChromXP C18-CL 3 μm via a nano-electrospray
source head and 10 μm inner diameter PicoTip (New Objective,
MA). The precolumn was washed for 10 min at 2 μL/min
with 2% ACN/0.1% FA. A gradient from 2% ACN/0.1% FA (v/v)
to 50% I/0.1% FA (v/v) in 90 min was applied at a flow rate of
300 nL/min.
The MS was operated in positive ion mode with survey
scans of 250 ms, and with an MS/MS accumulation time of
100 ms for the 25 most intense ions (total cycle time 2.5 s). A
threshold for triggering of MS/MS of 100 counts per second
was used, together with dynamic exclusion for 12 s and
rolling collision energy, adjusted for the use of iTRAQ reagent
in the Analyst method. Information-dependent acquisition
was powered by Analyst TF 1.5.1 software, using mass rangesof 400–1600 amu in MS and 100–1400 amu in MS/MS. The
instrument was automatically calibrated after every fifth
sample using a beta-galactosidase digest.
2.8. iTRAQ protein identification and statistical analyses
Liver samples from wild type and Nrf2(−/−) mice, treated with
CDDO-me or DMSO vehicle control, were analysed across four
iTRAQ runs with a comparator pooled sample incorporated in
each run for normalisation between iTRAQ experiments.
Samples (n = 6) for each treatment were randomised across
the four runs to minimise label bias. Ratios for each iTRAQ
label were obtained, using the common pool as the denom-
inator (iTRAQ label 113). Data analysis was performed
using ProteinPilot software (version 3, Applied Biosystems,
Warrington, UK). The data were analysed with MMTS as a
fixed modification of cysteine and biological modifications.
The SwissProt database was searched with a confidence
interval of 95% and also screened in reverse to facilitate false
discovery rate (FDR) analysis. Proteins identified from pep-
tides with more than 95% confidence and a global FDR of less
than 1% were included in the statistical analysis.
The limma package within the R programming environ-
ment [32] allowed simultaneous comparisons between multi-
ple treatments using design and contrast matrices. This open
source software generates a linear regression model (lm) to
facilitate the analysis of differential protein expression. Mean
fold changes were calculated and analysis was conducted on
the logged fold-change values. Unadjusted (raw) P values and
P values following Benjamini–Hochberg (BH) correction for
multiple testing were determined.
Nrf2- and CDDO-me-dependent protein expression was
defined by comparing Nrf2(−/−) DMSO with wild type DMSO
(group A), wild type DMSO with wild type CDDO-me (group B)
and Nrf2(−/−) DMSO with Nrf2(−/−) CDDO-me mice (group C). The
resulting protein lists for genetic disruption and pharmacolog-
ical pathway activationwere compared to identify changes that
were both common and unique to Nrf2 and CDDO-me in a similar
manner to the gene expression studies performed in Keap1(−/−)
and triterpenoid treated mice reported by Yates et al. [33].
2.9. Ontology and pathway analysis
Pathway analysis was performed as previously described using
MetaCore fromGeneGo Inc [3]. The softwarewas used in order to
identify the pathways most significantly differentially regulated
in livers of wild type and Nrf2(−/−) mice as well as in wild type
vehicle control and wild type CDDO-me treated animals.
2.10. Immunoblotting for Nrf2 target proteins
In order to confirm the iTRAQ-identified expression changes in
key Nrf2- and CDDO-driven gene targets, western immunoblot-
ting was undertaken for NQO1, ACL, CYP2A5 and ENTPD5 using
methodsas describedpreviously [3]. Apolyclonal goat anti-NQO1
antibody (ab2346, Abcam plc, Cambridge, UK) was used at a
dilution of 1:5000, while a monoclonal rabbit anti-ENTPD5
antibody (ab108603,Abcamplc)wasusedat 1:10,000. The chicken
anti-CYP2A5antibodywasgenerouslyprovidedbyRisto Juvonen,
University of Eastern Finland, Kuopio, Finland.
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Proteins that were found to be regulated by Nrf2 at both the
constitutive and inducible levels were subjected to enhancer
element binding site analysis using the Genomatix software
suite (v3.1). Full length gene and promoter (3000 bp) DNA
sequences were interrogated for consensus Nrf2 binding sites
using the MatInspector search [34] within the MAF and AP1
related factor subgroup (V$AP1R). Full length gene sequences
were retrieved from Entrez gene and promoter sequences were
extracted using the Genomatix Gene2Promoter tool. Matrix
similarity was optimised and the core similarity threshold was
set to 0.75.3. Results
3.1. Induction of Nrf2 by CDDO-me
Preliminary studieswere performed in order to determine a dose
of CDDO-me and a suitable timepoint thatwould enable analysis
of downstreamprotein expression in the liver resulting fromNrf20
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Fig. 1 – Immunoblots of liver homogenates from pilot study
wild type mice treated with CDDO-me in DMSO (i.p.).
Immunoblots for NQO1 were used in order to determine the
dose (a) and duration (b) of CDDO-me treatment that results
in maximum NQO1 induction. Densitometric analysis of the
immunoblots shows NQO1 expressed relative to actin. Error
bars represent SEM (n = 2, a; n = 4, b).induction after a single administration. The dose range usedwas
based on a study in ICRmice [19]. Nrf2 inductionwas determined
by NQO1 western immunoblotting (Fig. 1). The 24 h timepoint
and a dose of 3 mg/kg CDDO-me were found to produce the
highest NQO1 signal, with the response diminishing at higher
doses. Consequently 24 h exposure to 3 mg/kg CDDO-me was
selected for future use.
Induction of Nrf2 at this dose in the subsequent study was
confirmed by analysis of NQO1. Fig. 2 shows a representative blot
of NQO1 levels in each treatment group and densitometric
analysis of expression of NQO1 in all animals in the study (n = 6).
Administration of CDDO-me resulted in a two-fold increase in
NQO1 in wild type animals at 24 h but no change in the Nrf2(−/−)
mice. NQO1 was expressed at a level that was 8-fold lower
in Nrf2(−/−) control animals when compared to their wild type
counterparts.
3.2. Microfludic TaqMan low density array (TLDA) cards
Microfluidic TLDA cardswere custom-designed. Each card allows
the simultaneous amplification of 48 gene targets in 8 samples.
Target geneswere selected on the basis of our previous proteome
comparison of Nrf2(−/−) and wild type mice. These were either
directly identified as Nrf2-regulated or were shown by MetaCore
analysis to reside in Nrf2-regulated pathways [3].
cDNA reverse transcribed from RNA extracted from the
livers of vehicle control and CDDO-me treated wild type and
Nrf2(−/−) mice (n = 8) was amplified using real-time PCR, with
data analysed using the ΔΔCT method. Pooled cDNA from all
sampleswas included on each plate, and expression of all other0.0
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Fig. 2 – Immunoblots of liver homogenates from wild type
and Nrf2(−/−) mice treated with CDDO-me in DMSO (i.p.) and
culled 24 h later. Densitometric analysis of the immunoblots
shows NQO1 expressed relative to actin. Error bars represent
SEM (n = 6). Statistical analysis was performed using a two
way ANOVA with Tukey multiple comparison testing. NQO1
expressionwas compared inwild type vehicle and CDDO-me
treated mice (***P < 0.001), vehicle treated wild type and
Nrf2(−/−) mice (###P < 0.001), and Nrf2(−/−) vehicle and
CDDO-me treated mice (no statistical difference).
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normalised to expression of the housekeeping gene 18S rRNA.
Statistical analysis was conducted on all genes for which
complete data sets were obtained in >4 of the 8 samples. On
this basis, five of the genes, Abcc1, Abcc4, Bhmt, Fabp5 and Prdx6,
were excluded. The mean relative expression of each gene was
calculated and standard error of the mean was determined
(Fig. 3).
The expression of genes was compared in wild type vehicle
control treated and wild type CDDO-me treatedmice, wild type
and Nrf2(−/−) vehicle control treated mice and Nrf2(−/−) vehicle
control and Nrf2(−/−) CDDO-me treated mice (two way ANOVA0
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Fig. 3 – Relative expression of mRNA in livers of wild type and Nr
detected by Microfluidic TaqMan low density array analysis. Lev
GSTA4, GSTM1, GSTP1, MGST, GCLC and CYP1A2 were statistical
when compared to vehicle control (*), while CES1G, CYP2C50 and
control animals when compared to their wild type counterparts
CDDO-me and vehicle control treated Nrf2(−/−) animals. Statistica
Tukey multiple comparison testing.with Tukey multiple comparison testing). Eleven genes, Gstm1,
Ephx, Ugt2b5, Gstp1, Nqo1, Mgst, Ces1g, Cyp1a2, Gsta4, Ugt1a6a
and Gclc, were expressed at a significantly higher level in wild
type CDDO-me treated animals when compared to the vehicle
control group, while three genes, Ces1g, Cyp2c50 and Lipg, were
expressed at a significantly lower level in the Nrf2(−/−) control
treated mice when compared to their wild type counterparts.
None of the genes were significantly differentially expressed
when theNrf2(−/−) vehicle control andNrf2(−/−) CDDO-me treated
groups were compared. The genes that were up-regulated with
CDDO-me treatment in wild type animal are associated with
drug metabolism and their regulation by Nrf2 has been well***
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(#). There was no statistical difference in mRNA levels of
l significance was assessed using a two way ANOVA with
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genes that were included in the TLDA analysis was not
significantly altered with CDDO-me treatment.
Nrf2 mRNAwas expressed in the Nrf2(−/−) animals; however,
this is consistent with the molecular lesion introduced, in
which exon 5 of the Nrf2 gene is absent, rendering the Nrf2
protein non-functional. This is in line with results of previous
studies [35].
3.3. Characterization of the constitutive Nrf2-responsive
hepatic proteome
A comparative iTRAQ-based proteomic analysis of livers from
Nrf2(−/−) and wild type mice was conducted. In order to define
Nrf2-dependent expression of proteins at both the basal and
inducible (24 h post dosing) levels, proteinswere extracted from
both DMSO vehicle treatedmouse livers and those treated with
CDDO-me (3 mg/kg). Proteome profiling of all mouse liver
samples yielded 3655 unique identifications at an FDR of <1%.
From this total, 1521 were shown to be quantifiable in at least
four mice belonging to each of the four treatment groups, and
these proteins were incorporated in the full statistical analysis.
Table 1 includes the list of 87 proteins that were up- or
down-regulated by at least 30% (P < 0.05) in Nrf2(−/−) mice
when compared to wild type animals at the basal level. By
applying a relatively non-stringent statistical analysis (without
correction formultiple testing), a total of 161 liver proteins were
deemed statistically different between wild type and Nrf2(−/−)
mice (irrespective of the fold change), and are detailed in
Supplementary Table 1.Whilst this level of statistical analysis is
insufficient for unequivocal designation of Nrf2-driven pro-
teins, it yields a sufficient number of nominally Nrf2-regulated
proteins to provide candidates for biomarker assessment and to
allow meaningful ontology and pathway analysis. As noted by
Subramanian et al. [36], the application of stringent multiple
testing correction algorithms (such as Bonferroni or Benjamini
Hochberg analyses) to large scale global analysis data can
preclude the identification of modest expression changes
that can collectively modulate a specific pathway. Of the 161
Nrf2-regulated proteins identified, 94 were expressed at a lower
level in the Nrf2(−/−) mice and 67 were up-regulated. This is in
line with our previous study, and with genomic studies, which
show both positive and negative regulation through the Nrf2
transcription pathway. Protein expression differences between
Nrf2(−/−) and wild type animals were evaluated to identify the
primary biological functions and pathways associated with
these genes. Analysis using MetaCore identified 48 pathways
that were significantly differentially regulated in the livers of
wild type and Nrf2(−/−) mice (Table 2; P < 0.05).
3.4. Characterization of the CDDO-me inducible Nrf2-dependent
hepatic proteome
Following administration of CDDO-me, 43 proteins were
either up- or down-regulated in wild type mice. Of these,
only 2 were similarly altered in Nrf2(−/−) mice. Complete lists of
proteins whose expression was altered by CDDO-me in wild
type and Nrf2(−/−) mice are provided in Supplementary Tables
2 and 3, respectively. These data are displayed graphically in
Fig. 4, which presents the fold difference for each individualprotein identified in at least 4 mice (1521 in total) plotted
against the P value; Fig. 4A represents the comparison
between wild type and Nrf2(−/−) mice at the basal level, whilst
the effect of CDDO-me treatment in wild type animals is
shown in Fig. 4B. Inspection of these plots suggests that the
influence of Nrf2 upon the basal proteome may be generally
more profound than the effect of acute induction. Overall,
more proteins lie above the statistical cut-off of P < 0.05
with the comparison at the basal level than are statistically
induced by CDDO-me. Moreover, with the exception of
CYP2A5 (labelled in Fig. 4B), the fold differences between
wild type and Nrf2(−/−) mice at the constitutive level comprised
a far greater range than those following CDDO-me treatment.
It is also notable that a sizable proportion of proteins were
expressed at a lower level in the wild type animals than in the
Nrf2(−/−) animals, indicating a level of negative regulation by
Nrf2. In contrast, the majority of the changes observed
following CDDO-treatment were up-regulations. The proteins
up- or down-regulated by at least 30% in wild type and Nrf2(−/−)
mice are included in Table 1. In wild type animals, 18 proteins
were induced compared with just 4 whose expression was
decreased after CDDO-me. Of the 18 protein induced, 16 were
uniquely up-regulated in wild type but not in Nrf2(−/−) animals.
As with the constitutively regulated proteins, proteins in-
duced by CDDO-me were heavily dominated by drug metab-
olizing enzymes and proteins involved in lipid synthesis/
metabolism. Notably, however, there was no indication
that CDDO-me resulted in a reduced expression of proteins
involved in fatty acid synthesis. A negative regulation of such
proteins, including ACL, fatty acid synthase and acyl coA
desaturase, at the constitutive level was observed both in the
current iTRAQ analysis and in our previous investigation [3]. A
similar effect has been shown at themRNA level by Tanaka et al.
[37]. CDDO-im has also been shown by other groups to cause
down-regulation of genes involved in the synthesis of fatty acid
at the mRNA level in wild type mice [33,38] but this was not
confirmed at the mRNA or protein level in our study with
CDDO-me. Several of the key lipid metabolic enzymes showed
a numerically reduced expression following CDDO-me, such as
ACL, which showed a 25% reduction following induction. These
values were not statistically significant.
Analysis using MetaCore identified 8 pathways that were
significantly altered in the livers of wild type mice treated
with CDDO-me, when compared to vehicle control treated
mice (Table 3; P < 0.05).
3.5. Characterisation of proteins regulated by Nrf2 at both
basal and CDDO-me inducible level
Six proteins were basally expressed at a significantly lower
level in Nrf2(−/−) when compared to wild type and were also
significantly up-regulated following CDDO-me treatment in
wild type mice, with expression differences in each case of
>30%. A summary of the function of the proteins is given
in Table 4. Of the proteins identified as most significantly
regulated by Nrf2, GSTM3, GSTM1 and EPXH1 are well
characterised as Nrf2-regulated proteins. The regulation of
CYP2A5 and UDPGDH by Nrf2 has also been noted previously
[4,39]. However, as far as we are aware, Nrf2 regulation of
ENTPD5 at the protein level is a novel finding of this study.
Table 1 – Constitutively regulated and CDDO-me inducible proteins. iTRAQ-based proteomic comparison of liver proteins in
vehicle treated and CDDO-me treated Nrf2(−/−) and wild type mice. Proteins whose expression was down-regulated or
up-regulated by at least 30% (P < 0.05) in vehicle treated Nrf2(−/−) relative to wild type mice, in wild type mice following
CDDO-me administration or in Nrf2(−/−) mice following CDDO-me administration are listed. Mean expression values relative
to a common pool are given for n = 4–6 animals. In the first instance, proteins are ordered according to the ratio between
wild type and Nrf2(−/−) mice (Nrf2(+/+)/Nrf2(−/−); highest to lowest) such that proteins whose expression is most markedly
constitutively reduced in Nrf2(−/−) animals appear at the top of the list. Remaining proteins are then ordered according to the
ratio between CDDO-me treated wild typemice and vehicle treated wild typemice (Nrf2(+/+)CDDO/Nrf2(+/+); highest to lowest)
such that proteins whose expression is most markedly induced by CDDO-me in wild type mice appear highest in the list.
Finally, proteins are ordered according to the ratio between CDDO-me treated Nrf2(−/−) mice and vehicle treated Nrf2(−/−) mice
(Nrf2(−/−) CDDO/Nrf2(−/−); highest to lowest) such that proteins whose expression is most markedly induced by CDDO-me in
Nrf2(−/−) mice appear highest in the list. Complete lists of all significantly altered proteins in wild type relative to Nrf2(−/−)
mice and all proteins significantly altered by CDDO-me in wild type and Nrf2(−/−) mice are given in Supplementary Tables 1,
2 and 3 respectively.
UniProt
accession
Name Peptides a Nrf2(+/+)
Nrf2(−/−)
P value Nrf2(+/+)
CDDO
Nrf2(+/+)
P value Nrf2(−/−)
CDDO
Nrf2(−/−)
P value
P17717 UDP-glucuronosyltransferase 2B17 38 4.28 <0.001
P10649 Glutathione S-transferase Mu 1 69 4.11 <0.001 1.43 0.022
P19639 Glutathione S-transferase Mu 3 49 4.04 <0.001 1.58 <0.001
P02762 Major urinary protein 6 35 3.62 <0.001
O70475 UDP-glucose 6-dehydrogenase 24 2.64 <0.001 1.57 <0.001
Q8VCC2 Liver carboxylesterase 1 13 2.64 0.030
P97493 Thioredoxin, mitochondrial 4 2.52 0.026
P30115 Glutathione S-transferase A3 30 2.42 0.007
Q9WUZ9 Ectonucleoside triphosphate
diphosphohydrolase 5
8 2.22 0.014 2.04 <0.001
P24549 Retinal dehydrogenase 1 68 2.17 <0.001
O08709 Peroxiredoxin-6 34 2.16 <0.001
P20852 Cytochrome P450 2A5 11 2.12 0.046 8.12 <0.001
P19157 Glutathione S-transferase P 1 124 2.12 0.002
P15626 Glutathione S-transferase Mu 2 37 2.09 <0.001
Q60991 25-hydroxycholesterol 7-alpha-hydroxylase 11 2.09 0.012
P22907 Porphobilinogen deaminase 7 2.04 <0.001
Q9D379 Epoxide hydrolase 1 14 2.00 0.001 1.48 0.002
P06801 NADP-dependent malic enzyme 35 1.91 <0.001
Q6XVG2 Cytochrome P450 2C54 16 1.88 <0.001 0.67 0.009
Q91X77 Cytochrome P450 2C50 21 1.79 0.002
Q9CXN7 Phenazine biosynthesis-like
domain-containing protein 2
15 1.70 0.001
Q8R0Y6 Cytosolic 10-formyltetrahydrofolate
dehydrogenase
113 1.70 0.001
Q9D1L0 Coiled-coil-helix-coiled-coil-helix
domain-containing protein 2,
mitochondrial
4 1.69 0.016
Q63836 Selenium-binding protein 2 131 1.67 0.040
Q9DBG1 Sterol 26-hydroxylase, mitochondrial 29 1.66 0.026
Q9DCY0 Glycine N-acyltransferase-like protein Keg1 12 1.65 0.001 0.56 0.021
Q91VA0 Acyl-coenzyme A synthetase ACSM1,
mitochondrial
42 1.64 <0.001
O88487 Cytoplasmic dynein 1 intermediate chain 2 4 1.63 0.003
Q9QZX7 Serine racemase 1 1.62 0.002
Q91VS7 Microsomal glutathione S-transferase 1 32 1.62 0.046
Q8VC30 Bifunctional ATP-dependent dihydroxyace-
tone kinase/FAD-AMP lyase (cyclizing)
77 1.60 0.039
P24472 Glutathione S-transferase A4 8 1.58 0.003
Q64442 Sorbitol dehydrogenase 36 1.58 <0.001
Q64458 Cytochrome P450 2C29 26 1.56 0.029
P52760 Ribonuclease UK114 35 1.55 <0.001
O70570 Polymeric immunoglobulin receptor 3 1.55 <0.001
Q9EQK5 Major vault protein 14 1.55 <0.001
Q922Q8 Leucine-rich repeat-containing protein 59 10 1.52 0.008
Q8CG76 Aflatoxin B1 aldehyde reductase member 2 10 1.51 <0.001
O55022 Membrane-associated progesterone
receptor component 1
9 1.50 0.019
Q80W22 Threonine synthase-like 2 8 1.49 0.002
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Table 1 (continued)
UniProt
accession
Name Peptides a Nrf2(+/+)
Nrf2(−/−)
P value Nrf2(+/+)
CDDO
Nrf2(+/+)
P value Nrf2(−/−)
CDDO
Nrf2(−/−)
P value
P61922 4-aminobutyrate aminotransferase,
mitochondrial
28 1.49 0.036
Q9DCM0 Protein ETHE1, mitochondrial 8 1.48 0.003
Q91V76 Ester hydrolase C11orf54 homolog 13 1.48 0.002
P15105 Glutamine synthetase 34 1.46 0.031
Q14CH1 Molybdenum cofactor sulfurase 2 1.46 0.025
O88844 Isocitrate dehydrogenase [NADP]
cytoplasmic
55 1.46 0.023
Q9R0P3 S-formylglutathione hydrolase 19 1.45 0.002
P63101 14-3-3 protein zeta/delta 21 1.43 0.015
P50431 Serine hydroxymethyltransferase, cytosolic 19 1.43 0.016
P70398 Probable ubiquitin carboxyl-terminal hy-
drolase FAF-X
7 1.42 0.041 0.64 0.011
O08966 Solute carrier family 22 member 1 2 1.42 0.034
Q91X52 L-xylulose reductase 7 1.41 0.035
Q9JII6 Alcohol dehydrogenase [NADP+] 20 1.39 0.012
Q8K1N1 Calcium-independent phospholipase
A2-gamma
3 1.39 0.023
P47738 Aldehyde dehydrogenase, mitochondrial 119 1.38 0.036
Q91YP3 Putative deoxyribose-phosphate aldolase 4 1.38 0.029
Q9DBG5 Perilipin-3 5 1.37 0.021
Q64514 Tripeptidyl-peptidase 2 10 1.37 0.012
Q64737 Trifunctional purine biosynthetic protein
adenosine-3
8 1.37 0.042
Q8VCA8 Secernin-2 13 1.36 0.022
P28474 Alcohol dehydrogenase class-3 24 1.35 0.018
Q3UJU9 Regulator of microtubule dynamics protein
3
7 1.35 <0.001
Q8K157 Aldose 1-epimerase 8 1.33 0.014
Q9Z2W0 Aspartyl aminopeptidase 7 1.32 0.013
Q99KQ4 Nicotinamide phosphoribosyltransferase 6 1.31 0.049
Q9WU79 Proline dehydrogenase 1, mitochondrial 22 1.30 0.046
Q9JMH6 Thioredoxin reductase 1, cytoplasmic 7 1.30 0.037
Q8C854 Myelin expression factor 2 1 0.70 0.002
Q811U4 Mitofusin-1 2 0.70 0.034
Q9D2G2 Dihydrolipoyllysine-residue
succinyltransferase component of
2-oxoglutarate dehydrogenase complex,
mitochondrial
14 0.70 0.049
Q64FW2 All-trans-retinol 13,14-reductase 8 0.69 0.041 0.55 0.004
P48678 Prelamin-A/C 18 0.68 0.002
Q4VBD2 Transmembrane anterior posterior
transformation protein 1
1 0.68 0.012 0.61 0.002
P25688 Uricase 36 0.67 0.027
Q8VEH5 EPM2A-interacting protein 1 2 0.67 0.019
P08032 Spectrin alpha chain, erythrocyte 7 0.66 0.005
P21981 Protein-glutamine
gamma-glutamyltransferase 2
16 0.66 0.049
Q9WU19 Hydroxyacid oxidase 1 9 0.65 <0.001
Q6ZWY9 Histone H2B type 1-C/E/G 30 0.65 0.020
O08917 Flotillin-1 2 0.63 0.002 0.69 0.018
P32020 Non-specific lipid-transfer protein 72 0.62 0.003
Q99P30 Peroxisomal coenzyme A diphosphatase
NUDT7
28 0.62 0.008
Q9CQC9 GTP-binding protein SAR1b 15 0.60 0.010 0.63 0.017
P11714 Cytochrome P450 2D9 42 0.58 0.008
Q05816 Fatty acid-binding protein, epidermal 8 0.40 0.003
O35728 Cytochrome P450 4A14 7 0.39 0.018 0.42 0.023
Q8JZK9 Hydroxymethylglutaryl-CoA synthase,
cytoplasmic
10 1.76 0.016
Q8C165 Probable carboxypeptidase PM20D1 4 1.64 0.049 1.73 0.047
P48758 Carbonyl reductase [NADPH] 1 18 1.63 <0.001
(continued on next page)
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Table 1 (continued)
UniProt
accession
Name Peptides a Nrf2(+/+)
Nrf2(−/−)
P value Nrf2(+/+)
CDDO
Nrf2(+/+)
P value Nrf2(−/−)
CDDO
Nrf2(−/−)
P value
Q9QYF1 Retinol dehydrogenase 11 2 1.52 0.042
P58044 Isopentenyl-diphosphate Delta-isomerase 1 3 1.48 0.037 1.63 0.015
P50285 Dimethylaniline monooxygenase
[N-oxide-forming] 1
18 1.45 0.001
Q9R1J0 Sterol-4-alpha-carboxylate
3-dehydrogenase, decarboxylating
8 1.42 0.034
Q07076 Annexin A7 4 1.42 0.003
P38060 Hydroxymethylglutaryl-CoA lyase,
mitochondrial
21 1.34 0.017
Q9DD20 Methyltransferase-like protein 7B 15 1.33 0.015
Q923D2 Flavin reductase (NADPH) 9 1.33 0.004
P29341 Polyadenylate-binding protein 1 18 1.32 0.014
Q91Y97 Fructose-bisphosphate aldolase B 111 0.69 0.037
P70255 Nuclear factor 1 C-type 1 0.61 0.012
P09103 Protein disulfide-isomerase 83 1.53 0.028
Q8VCM7 Fibrinogen gamma chain 11 1.52 <0.001
P62082 40S ribosomal protein S7 17 1.49 0.013
P19324 Serpin H1 3 1.47 0.044
Q9DBG7 Signal recognition particle receptor subunit
alpha
4 1.47 0.019
P24369 Peptidyl-prolyl cis-trans isomerase B 8 1.46 0.017
Q8QZZ7 TP53RK-binding protein 1 1.46 0.042
P27773 Protein disulfide-isomerase A3 49 1.44 0.016
O08600 Endonuclease G, mitochondrial 3 1.40 0.004
Q9JHK4 Geranylgeranyl transferase type-2 subunit
alpha
2 1.40 0.010
P18760 Cofilin-1 14 1.39 0.013
Q922E4 Ethanolamine-phosphate
cytidylyltransferase
9 1.37 0.012
Q8BW75 Amine oxidase [flavin-containing] B 18 1.37 0.013
P49722 Proteasome subunit alpha type-2 11 1.37 0.024
P99027 60S acidic ribosomal protein P2 19 1.36 0.020
Q9CQF9 Prenylcysteine oxidase 5 1.36 0.036
P14211 Calreticulin 24 1.36 0.038
O08795 Glucosidase 2 subunit beta 6 1.34 0.001
Q921M3 Splicing factor 3B subunit 3 4 1.34 0.009
O70503 Estradiol 17-beta-dehydrogenase 12 6 1.33 0.032
Q9DCM2 Glutathione S-transferase kappa 1 9 1.33 0.040
P62702 40S ribosomal protein S4, X isoform 13 1.33 0.043
P47962 60S ribosomal protein L5 13 1.32 0.024
Q60866 Phosphotriesterase-related protein 7 1.31 0.006
Q9CXI5 Mesencephalic astrocyte-derived neuro-
trophic factor
4 1.30 0.033
P62827 GTP-binding nuclear protein Ran 6 1.30 0.042
Q3ULD5 Methylcrotonoyl-CoA carboxylase beta
chain, mitochondrial
14 0.58 <0.001
O09158 Cytochrome P450 3A25 4 0.54 0.032
Q64459 Cytochrome P450 3A11 27 0.46 <0.001
Q99LY9 NADH dehydrogenase [ubiquinone]
iron-sulfur protein 5
2 0.46 0.031
O88833 Cytochrome P450 4A10 9 0.29 0.012
O35386 Phytanoyl-CoA dioxygenase, peroxisomal 5 1.70 0.008
Q91WL5 Cytochrome P450 4A12A 17 0.60 0.024
P61924 Coatomer subunit zeta-1 1 0.67 0.040
Q62189 U1 small nuclear ribonucleoprotein A 1 0.67 0.017
P55050 Fatty acid-binding protein, intestinal 2 0.69 0.028
Q99L13 3-hydroxyisobutyrate dehydrogenase,
mitochondrial
14 0.69 0.041
Q9Z0M5 Lysosomal acid lipase/cholesteryl ester
hydrolase
5 0.70 0.031
a Average number of peptides used for quantification across the four individual iTRAQ runs.
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Table 2 – Pathway analysis of Nrf2-regulated gene products at the basal level. GeneGo Metacore was used to identify
pathways enriched in the wild type animals compared with the Nrf2(−/−) mice. All significant (P < 0.05) pathways are listed
along with the number of objects within the protein set associated with that pathway. The total number of objects in the
entire pathway is shown in parentheses.
Pathway P value Objects
1 Pyruvate metabolism/rodent version 0.0000040 7 (66)
2 NRF2 regulation of oxidative stress response 0.000016 6 (54)
3 Naphthalene metabolism 0.000032 6 (61)
4 Glutathione metabolism/rodent version 0.000075 6 (71)
5 Glutathione metabolism 0.00048 5 (65)
6 Glutathione metabolism/human version 0.00051 5 (66)
7 Tryptophan metabolism/rodent version 0.00055 6 (102)
8 CAR-mediated direct regulation of xenobiotic metabolizing enzymes/rodent version 0.00074 4 (41)
9 CAR-mediated direct regulation of xenobiotic metabolizing enzymes/human version 0.00074 4 (41)
10 Pyruvate metabolism 0.0015 4 (49)
11 Lysine metabolism/rodent version 0.0018 5 (87)
12 Transcription_Transcription regulation of aminoacid metabolism 0.0019 3 (25)
13 Folic acid metabolism 0.0019 4 (53)
14 Triacylglycerol metabolism p.1 0.0031 4 (60)
15 Tryptophan metabolism 0.0035 5 (101)
16 Ascorbate metabolism/rodent version 0.0036 3 (31)
17 Butanoate metabolism 0.0037 4 (63)
18 Development_EPO-induced Jak-STAT pathway 0.0051 3 (35)
19 Retinol metabolism/rodent version 0.0053 4 (70)
20 Transcription_Role of AP-1 in regulation of cellular metabolism 0.0065 3 (38)
21 Retinol metabolism 0.0065 4 (74)
22 Propionate metabolism p.1 0.0070 3 (39)
23 Histidine-glutamate-glutamine and proline metabolism/rodent version 0.0072 5 (120)
24 Leucine, isoleucine and valine metabolism/rodent version 0.0085 4 (80)
25 Benzo[a]pyrene metabolism 0.0086 3 (42)
26 Immune response_IL-7 signaling in B lymphocytes 0.0092 3 (43)
27 Immune response_IL-5 signalling 0.0098 3 (44)
28 Lysine metabolism 0.011 4 (85)
29 Mechanisms of CFTR activation by S-nitrosoglutathione (normal and CF) 0.011 3 (46)
30 Androstenedione and testosterone biosynthesis and metabolism p.1 0.016 3 (53)
31 Immune response_Fc epsilon RI pathway 0.018 3 (55)
32 Androstenedione and testosterone biosynthesis and metabolism p.1/rodent version 0.020 3 (57)
33 Immune response_CCR5 signaling in macrophages and T lymphocytes 0.021 3 (58)
34 Propionate metabolism p.2 0.029 3 (66)
35 Polyamine metabolism 0.031 3 (68)
36 Acetaminophen metabolism 0.034 2 (29)
37 Histamine metabolism 0.034 2 (29)
38 Immune response_Signaling pathway mediated by IL-6 and IL-1 0.036 2 (30)
39 Cholesterol and sphingolipids transport/distribution to the intracellular membrane compartments (normal and CF) 0.039 2 (31)
40 Beta-alanine metabolism/rodent version 0.041 2 (32)
41 Signal transduction_ERK1/2 signaling pathway 0.041 2 (32)
42 (L)-Arginine metabolism 0.041 3 (76)
43 Leucine, isoleucine and valine metabolism.p.2 0.044 3 (78)
44 Development_CNTF receptor signalling 0.046 2 (34)
45 Fatty acid omega oxidation 0.046 2 (34)
46 Immune response_Role of the Membrane attack complex in cell survival 0.046 2 (34)
47 Immune response_Oncostatin M signaling via MAPK in mouse cells 0.048 2 (35)
48 Estrone metabolism 0.048 2 (35)
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CYP2A5 and ENTPD5 by Nrf2
Western immunoblotting was performed in order to validate
the differences noted in expression of CYP2A5 and ENTPD5
(Figs. 5 and 6 respectively). Densitometric analysis of immu-
noblots identified a 2.4-fold induction in CYP2A5 levels in wild
type mice treated with CDDO-me when compared to vehicle
control mice, while no induction was identified in Nrf2(−/−)
mice treated with the triterpenoid. Expression of CYP2A5
was 7.4-fold lower in vehicle control Nrf2(−/−) animals whencompared to their wild type counterparts. ENTPD5 expression
was induced 2.3-fold in CDDO-me treated wild type animals,
with no induction in Nrf2(−/−) mice. Furthermore, comparison
of the vehicle control groups showed that ENTPD5 expression
was reduced by 4.6-fold in Nrf2(−/−) animals.
3.7. ACL in CDDO-me treated mice
In order to further investigate potential differences in fatty
acid metabolism enzymes in vehicle control and CDDO-me
treated wild type mice, a western immunoblot for ACL was
Wild type/Nrf2(-/-) Wild type CDDO-me/Wild type
Fig. 4 – Volcano plots of the proteins quantified during iTRAQ analysis comparing (a) wild type vehicle control and Nrf2(−/−)
vehicle control and (b) wild type CDDO-me and wild type vehicle control mice. Each point represents the difference in
expression (fold-change) between the two groups of mice plotted against the level of statistical significance. Dotted vertical
lines represent differential expression differences of ±30%, while the dotted horizontal line represents a significance level of
P < 0.05. Proteins represented by a filled yellow square are those with expression that differs by at least 30% at a statistically
significant level.
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showing that there was no statistical difference in expression
of the protein between wild type animals in the vehicle
control and those treated with CDDO-me.
3.8. Enhancer element binding site analysis of the proteins
regulated by Nrf2 at both the constitutive and inducible levels
The Genomatix software suite was used in order to interro-
gate full length gene and promoter (3000 bp) DNA sequences
from proteins identified as regulated by Nrf2 at both the
constitutive and inducible levels for consensus Nrf2 binding
sites. Results presented in Supplementary Table 4 focus on
three transcription factor binding sites within the MAF andTable 3 – Pathway analysis of Nrf2-regulated gene
products induced by CDDO-me. GeneGo Metacore was
used to identify pathways enriched in the wild type
animals treated with CDDO-me (3 mg/kg) for 24 h
compared with the vehicle treated wild type mice. All
significant (P < 0.05) pathways are listed along with the
number of objects within the protein set associated with
that pathway. The total number of objects in the entire
pathway is shown in parentheses.
Pathway P value Objects
1 Glycolysis and gluconeogenesis (short map) 0.0015 3 (66)
2 Cholesterol biosynthesis 0.0034 3 (88)
3 Glycogen metabolism 0.0076 2 (38)
4 SCAP/SREBP transcriptional control of
cholesterol and FA biosynthesis
0.0084 2 (40)
5 Galactose metabolism 0.018 2 (59)
6 Fructose metabolism 0.027 2 (74)
7 Peroxisomal branched chain fatty acid
oxidation
0.033 2 (83)
8 Fructose metabolism/rodent version 0.034 2 (84)AP1 related factor subgroup: NF-E2 p45, antioxidant response
elements and binding sites for heterodimers with small
Maf-proteins. Thirty-two consensus binding sites were iden-
tified in the Entpd5 gene (8 in the promoter region and a
further 24 in the full length sequence), 13 in the Cyp2a5 gene
(2 in the promoter region, 11 in the full length sequence), 9 in
the Gstm3 gene (7 in the promoter region and 2 in the full
length gene), 2 in the Gstm1 gene (2 in the full length gene), 34
in the Ephx1 gene (11 in the promoter and 23 in the full length
gene) and 19 in the Ugdh gene (12 in the promoter and 7 in the
full length gene).4. Discussion
Loss of Nrf2 signalling in the Nrf2(−/−) mouse model has
been shown to increase susceptibility to various forms of
chemical-induced pathologies, including hepatotoxicity asso-
ciated with acetaminophen [5,6] and carbon tetrachloride [7],
lung damage induced by butylated hydroxyl toluene [40] and
lipopolysaccharide-induced sepsis [41]. These studies in-
volved acute administration of single doses of the chemical
toxins, suggesting that the enhanced susceptibility in the
Nrf2(−/−) animals was due to lower basal expression of cellular
defence proteins, rather than an abrogated ability to respond
to the treatment by up-regulation of the Nrf2-driven genes,
since it is unlikely that such an adaptive response could occur
within the time-frame of the acute toxicity. This notion is
supported by our recent proteomic study of acetaminophen
(APAP) hepatotoxicity, which showed very few APAP-induced
changes at the protein level within the timeframe of the
toxic response (unpublished data). In other cases, such as the
neurotoxicity seen with MPTP, gastrointestinal toxicity
with dextran-sulphate and stomach neoplasias induced by
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administration of the toxins and this may reflect reduced
induction of a protective response in the Nrf2(−/−) animals.
Thus, both lower constitutive levels of Nrf2 regulated pro-
teins, as well as a reduced ability to up-regulate these proteins
are likely to contribute to the enhanced susceptibility of
Nrf2(−/−) mice to chemical stress. It is thus important to know
whether the same proteins are regulated at both constitutive
and inducible levels, or whether different populations of
cellular defence proteins may be involved in the acute and
chronic protection afforded by Nrf2 in these different animal
models. It is also important to define the dynamic range of
expression of Nrf2 proteins and how this might impact upon
the toxicity of specific chemicals and influence the suscepti-
bility of particular species and individuals in the human
population.
In our previous study [3] we compared the basal liver
proteomes of Nrf2(−/−) and wild type mice to identify proteins
involved in cellular defence against acute chemical insults;
however, no similar study has yet been carried out at the
protein level in an Nrf2-induced mouse model. Here, we have
extended our analysis to define the Nrf2-inducible protein
population using the most potent activator of Nrf2 currently
available, CDDO-me. CDDO-me was recently investigated in
man as a potential therapeutic agent for the treatment of type
2 diabetic kidney disease [42]. Other Nrf2 inducers are now
being developed for a range of therapeutic indications. For
example, dimethyl fumarate has recently been approved by
the FDA as a treatment for reducing the incidence of relapse in
multiple schlerosis patients [43]. Thus knowledge of the
pattern of protein induction becomes essential in order to
predict the biochemical, pharmacological and toxicological
consequences of sustained Nrf2 activation.
Overall, out of 1556 proteins identified and quantified, 161
proteins were different at the basal level between wild type
and Nrf2(−/−) mice, whereas only 43 were similarly altered
following CDDO-me treatment of wild type animals. What
was particularly striking, however, was the lack of overlap
between these two lists of proteins: only 6 proteins were both
lower in the Nrf2(−/−) mice and induced by CDDO-me in the
wild types. These were CYP2A5, GSTM3, GSTM1, ENTPD5,
UDPGDH and EPHX1. Superficially, this lack of concordance
between the basal and inducible protein populations suggests
that two discrete subsets of Nrf2 target proteins exist, one that
responds to a loss of Nrf2 and one that is up-regulated
following chemical activation of the Nrf2 signalling pathway,
with only a limited overlap between the two. Whilst this
concept has a plausible toxicological rationale, in that a cell’s
constitutive defence systemmust be wide-ranging and able to
counter a broad range of chemical insults, whereas an
inducible response can be tailored to the specific toxin to
which the cell is exposed, such an interpretation of these
proteomic data must be viewed with caution. Several differ-
ences exist between the two methods used to modulate Nrf2
activity, which could, either directly or indirectly, alter the
protein expression profiles at the basal and inducible levels.
First, the greater abundance of constitutively regulated
proteins may reflect longer term or compensatory changes
in the knockout animals, which would not be apparent
following a single, acute treatment with an inducing agent.Furthermore, although the 24 h post-CDDO-me timepoint
was optimum for NQO1 protein induction, this may not be
the case for all target proteins and thus a single “snapshot”
of the inducible proteome may not capture the entirety
of up-regulated proteins. Alternatively, it is possible that
CDDO-me causes Nrf2 activation in cell types other than
hepatocytes, for example, Kupffer or stellate cells, both of
which possess inducible Nrf2 pathways [44,45], and that the
observed protein changes from CDDO-me treatment could
result from secondary cell-to-cell signalling events. These
alternative explanations require further investigation before
concluding that the difference between the two proteomes is
due to alternative binding to, and activation of, enhancer
elements within target gene promoters. Nevertheless, the
results are consistent with a global transcriptomic study in
mouse embryonic fibroblasts (MEFs), which showed regula-
tion of distinct gene sets in genetic models of Nrf2 deletion
and induction [46].
CDDO and its various derivatives have been shown to
affect several different intracellular signalling pathways,
including NF-κB [27,28], STAT [24], ERK/SMAD [47,48] and
PPARγ [49]. A particular focus of this study was to compare
CDDO-me induced protein expression changes in Nrf2 com-
petent and deficient mice. This allows us to define any
changes observed as Nrf2 dependent or independent effects.
Somewhat surprisingly, very few of the proteins induced by
CDDO-me in wild type mice were similarly changed in the
Nrf2(−/−) animals, indicating that at the relatively low acute
dose of CDDO-me used here, nearly all of the protein changes
were mediated via the Keap1:Nrf2 signalling pathway.
With respect to defence against chemical toxins, a total of
65 proteins were detected that are directly involved in drug
metabolism (including CYPs, UDP-GTs, epoxide hydrolase and
glutathione transferases) and of these 21 were regulated by
Nrf2 at the basal level and 9 following treatment with
CDDO-me: only 5 drug metabolizing proteins were regulated
both basally and after induction. These data indicate that the
protein expression profile of Nrf2-regulated gene products is
finely tuned to deal with exposure to small chemical
xenobiotics that cause oxidative stress or the formation of
protein reactive electrophilies. As was shown in our previous
proteomic investigation of Nrf2(−/−) mice, lipid metabolism
featured strongly in the differentially regulated proteins,
confirming a key role for Nrf2 in the modulation of fatty acid
synthesis. The mechanism underlying this effect is not clear,
since the expression of fatty acid synthetic enzymes is
inversely related to Nrf2 activity, but may involve an
interaction with other regulators of lipid metabolism such as
PPARγ or sterol regulatory element-binding protein 1c
(SREBP1c). An effect of Nrf2 on expression of genes involved
in lipid metabolism has been noted at the mRNA level in
several other studies. Mice fed a high fat diet expressed genes
encoding enzymes key for fatty acid synthesis at a signifi-
cantly higher level in Nrf2(−/−) mice when compared to wild
type animals [37]. A similar effect was observed at the mRNA
level in an elegant study by Yates et al. [33] which compared
hepatic transcription profiles in mice following exposure to
another derivative of CDDO, CDDO-im, and in mice deficient
in Keap1, which thus had constitutively activated Nrf2. Both
chemical and genetic methods of Nrf2 induction resulted in
Table 4 – Proteins regulated by Nrf2 at both basal and CDDO-me-inducible levels. iTRAQ-based proteomic comparison of
liver proteins in vehicle control treated wild type and Nrf2(−/−) mice and CDDO-me treated wild type mice. Proteins whose
expression was up- or down-regulated by at least 30% at both the basal and CDDO-me-inducible level are listed. Mean
expression values relative to a common pool are given for n = 4–6 mice. Proteins are ordered according to the ratio between
CDDO-me treated wild type and Nrf2(−/−) mice (Nrf2(+/+) CDDO/Nrf2(−/−); highest to lowest), such that proteins showing the
widest range of Nrf2 regulation appear at the top of the list.
UniProt
accession
Name Nrf2(+/+)CDDO
Nrf2(−/−) ctrl
Protein functiona
P20852 Cytochrome P450 2A5 17.24 Cytochrome P450 exhibiting high coumarin 7-hydroxylase activity.
P19639 Glutathione S-transferase Mu 3 6.39 Mediates the conjugation of GSH to a wide number of exogenous and
endogenous electrophiles.
P10649 Glutathione S-transferase Mu 1 5.86 Mediates the conjugation of GSH to a wide number of exogenous and
endogenous electrophiles.
Q9WUZ9 Ectonucleoside triphosphate
diphosphohydrolase 5
4.55 Uridine diphosphatase that promotes protein N-glycosylation and ATP
regulation. With CMPK1 and AK1, constitutes an ATP hydrolysis cycle
converting ATP to AMP resulting in a compensatory increase in aerobic
glycolysis. Plays a key role in the AKT1-PTEN signalling pathway by
promoting glycolysis in proliferating cells in response to PI3K signalling.
O70475 UDP-glucose 6-dehydrogenase 4.14 Involved in the biosynthesis of UDPGA, glycosaminoglycans,
hyaluronan, chondroitin sulfate, and heparan sulphate.
Q9D379 Epoxide hydrolase 1 2.96 Enzyme that catalyzes the hydrolysis of arene and aliphatic epoxides to
less reactive and more water soluble dihydrodiols by the trans addition
of water.
a Protein function based on the UniProt database annotation (http://www.uniprot.org/).
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pathway, such as ACL. Interestingly, in the current study,
whilst wild type mice clearly under-expressed these proteins
compared with Nrf2(−/−) mice, treatment of wild type animals0.0
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Fig. 5 – CYP2A5 immunoblots of liver homogenates fromwild
type and Nrf2(−/−) mice treated with CDDO-me or DMSO
vehicle control (i.p.) and culled 24 h later. Densitometric
analysis of the immunoblots shows CYP2A5 expressed
relative to actin. Error bars represent SEM (n = 6). Statistical
analysis was performed using a twoway ANOVAwith Tukey
multiple comparison testing. CYP2A5 expression was
compared in wild type vehicle and CDDO-me treated mice
(***P < 0.001), vehicle treated wild type and Nrf2(−/−) mice
(###P < 0.001), and Nrf2(−/−) vehicle and CDDO-me treatedmice
(no statistical difference).with CDDO-me did not result in a further decrease in expression.
Thus the effects observed by Yates et al. at the mRNA level
may not translate into altered expression at the protein level. A
similar effect of CDDO-im was reported by Shin et al. [38] who0.0
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Fig. 6 – ENTPD5 immunoblots of liver homogenates fromwild
type and Nrf2(−/−) mice treated with CDDO-me or DMSO
vehicle control (i.p.) and culled 24 h later. Densitometric
analysis of the immunoblots shows ENTPD5 expressed
relative to actin. Error bars represent SEM (n = 6). Statistical
analysis was performed using a twoway ANOVAwith Tukey
multiple comparison testing. ENTPD5 expression was
compared in wild type vehicle and CDDO-me treated mice
(***P < 0.001), vehicle treated wild type and Nrf2(−/−) mice
(#P < 0.05), and Nrf2(−/−) vehicle and CDDO-me treated mice
(no statistical difference).
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Fig. 7 – ACL immunoblots of liver homogenates from wild
type mice treated with CDDO-me or DMSO vehicle control
(i.p.) and culled 24 h later. Densitometric analysis of the
immunoblots shows ACL expressed relative to actin. Error
bars represent SEM (n = 6). Statistical analysis was
performed using a Student’s t-test; there was no statistical
difference between the two groups.
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RT-PCR; however, this study involved prolonged treatment with
CDDO-im over several weeks and an effect on lipid metabolism
was not seen in mice after acute treatment with the inducer.
Nevertheless, it is clear that Nrf2 has an important role for
maintenance of lipid homeostasis in the liver; however, it
appears from this study that the influence of Nrf2 at the basal
level ismore importantwith respect to lipidmetabolism than the
effect of induction.
Of the proteins that were up-regulated in CDDO-me treated
wild typemice, CYP2A5 showed the greatest increase in protein
expression. Nrf2-regulation of CYP2A5 has previously been
documented [39,50], while studies employing human hepato-
cytes have also identified CYP2A6, the human analogue, asNrf2
regulated [51]. Interestingly, CYP2A5/6 is important for the
metabolism of compounds including coumarin, nicotine and
caffeine, with products of coumarin and caffeine metabolism
being employed asmarkers of enzyme activity [52,53]. Recently,
CYP2A5 has also been shown to be involved in bilirubin
clearance, and Nrf2-mediated regulation of CYP2A5 has been
identified as having a role in the cytoprotective response to
bilirubin-associated hepatotoxicity [54]. This may point to an
evolutionary role for Nrf2 in defence against bilirubin toxicity
through the co-ordinated phase I and II regulation metabolism.
ENTPD5 was another of the five proteins that was expressed
at a significantly higher level in wild type mice treated with
CDDO-me, as well as at a constitutively lower level in Nrf2(−/−)
animals. To our knowledge, Nrf2-mediated regulation of ENTPD5
at the protein level has not previously been documented,
although an association has been identified at the mRNA level.
Entpd5 was shown to be upregulated in microarray analysis of a
Keap1-deficient hepatocyte-specific mouse model [55] and its
regulation at both the constitutive and inducible levels is
consistent with a microarray/ChIP-Seq study that identified
Nrf2 target genes in genetically modified MEFs [46]. ENTPD5
is becoming recognised as a pivotal protein in the respiratoryswitch to aerobic glycolysis, theWarburg effect, inmany tumours
[56]. ENTPD5 is a uridine diphosphatase that hydrolyzes uridine
diphosphate (UDP) to uridine monophosphate (UMP). It is
important in the glycosylation and folding of proteins, as well
as in ATP regulation. It has been shown to play a role in
regulation of the PI3K-PTEN-AKT signalling loop [57]. Interest-
ingly, the PI3K/AKT signalling pathway has been implicated in
Nrf2 signalling, notably in the triterpenoid-mediated activation
of Nrf2 [18]. Furthermore, ENTPD5 deficient transgenic mice
show an unusual phenotypic pathology comprising swelling of
the hepatocytes within the centrilobular region, progressing to
hepatocellular neoplasia with time [58].
In conclusion, this study provides the first comprehensive
proteomic analysis of Nrf2-regulated liver protein expression
at the constitutive and CDDO-me inducible level. Whilst both
basal and inducible changes were observed, there was little
overlap between the two lists of proteins quantified. Never-
theless, the most prominent groups of proteins under both
conditions were those involved in the metabolism of xenobi-
otics, and thus, the study provides a clear rationale for the role
of Nrf2 in protection against chemical toxins following
both acute and chronic exposure. The definition of the Nrf2
inducible proteome in all organs, from a qualitative and
quantitative perspective, would provide a useful platform for
the development of Nrf2 inducers as therapeutic agents for the
treatment of diseases which have aetiologies based on either
chemical stress or chemical exposure. Furthermore, such
proteomic analysis should provide a basis for the discovery of
biomarkers which can be used to facilitate the translation of
basic biochemical science into clinical practice.
Supplementary data to this article can be found online at
http://dx.doi.org/10.1016/j.jprot.2014.05.007.Transparency Document
Transparency Document associated with this article can be
found, in the online version.Acknowledgements
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